DECAPRYN
LOE ApproachingNDAORALTABLET
Approved
Apr 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DECAPRYN is an oral tablet small-molecule drug approved in 1948 by Sanofi. The mechanism of action and specific indications are not publicly documented in available data. It represents a legacy product from the early pharmaceutical era with established clinical use.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting team focused on managed decline and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DECAPRYN currently shows zero linked job openings, reflecting its mature/declining lifecycle stage. Roles available on this product focus on managing market share erosion, negotiating with payers, and planning generic transition strategy.
Brand ManagerSenior Product Manager
Worked on DECAPRYN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.